Capsaicin patch license extension application withdrawn
21st March 2012
Astellas Pharma has withdrawn its application to the European Medicines Agency (EMA) for a license extension for Qutenza® (capsaicin 8% transdermal patch). The application was to extend the marketing authorization for Qutenza® to all adult patients with exclusion of patients with pain caused by diabetes.
The withdrawal was based on the Committee for Medicinal Products for Human Use (CHMP)'s view that the data provided would not allow the committee to conclude on a positive benefit-risk balance.
Qutenza® continues to be authorized for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults either alone or in combination with other medicinal products for pain.
- Cochrane review: hydromorphone for neuropathic pain
- Glycopyrronium oral solution authorized for severe drooling in the UK
- Management of chronic pain in adult cancer survivors
- RPS guide for pharmacists working in care homes
- FDA authorizes dronabinol oral solution
- CQC annual report: safer management of controlled drugs
- Citalopram suspected drug interaction with cocaine
- Thalidomide new risks
- Nasogastric tube misplacement: continuing risk of death and severe harm
- Improving the quality of care in the last days of life: A practical guide to getting the medications right